The novel antidiabetic agent, sodium glucose co-transporter 2 (SGLT2) inhibitor, is essential for overcoming the burden of diabetic and have beneficial cardiovascular and renal effects, especially in improving the prognosis of HF, which supports it as a foundational therapy for HF (153, 154). Here, SLC5A2 is linked to hydrops fetalis.